BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38389038)

  • 1. Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa.
    McNabb KC; Bergman AJ; Patil A; Lowensen K; Mthimkhulu N; Budhathoki C; Perrin N; Farley JE
    BMC Public Health; 2024 Feb; 24(1):578. PubMed ID: 38389038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss to follow-up among patients diagnosed with spinal tuberculosis at a tertiary hospital in Western Cape Province, South Africa: A retrospective cohort study.
    Mann TN; Davis JH; Dyers R
    S Afr Med J; 2020 Mar; 110(4):284-290. PubMed ID: 32657739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis.
    McIntosh AI; Jenkins HE; White LF; Barnard M; Thomson DR; Dolby T; Simpson J; Streicher EM; Kleinman MB; Ragan EJ; van Helden PD; Murray MB; Warren RM; Jacobson KR
    PLoS Med; 2018 Aug; 15(8):e1002638. PubMed ID: 30130377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.
    Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S
    PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa.
    Salaam-Dreyer Z; Streicher EM; Sirgel FA; Menardo F; Borrell S; Reinhard M; Doetsch A; Cudahy PGT; Mohr-Holland E; Daniels J; Dippenaar A; Nicol MP; Gagneux S; Warren RM; Cox H
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0036421. PubMed ID: 34460307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.
    Daniels JF; Khogali M; Mohr E; Cox V; Moyo S; Edginton M; Hinderaker SG; Meintjes G; Hughes J; De Azevedo V; van Cutsem G; Cox HS
    PLoS One; 2015; 10(11):e0142873. PubMed ID: 26555134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
    Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
    BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
    BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
    Cox H; Dickson-Hall L; Ndjeka N; Van't Hoog A; Grant A; Cobelens F; Stevens W; Nicol M
    PLoS Med; 2017 Feb; 14(2):e1002238. PubMed ID: 28222095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa.
    Leavitt SV; Jacobson KR; Ragan EJ; Bor J; Hughes J; Bouton TC; Dolby T; Warren RM; Jenkins HE
    Emerg Infect Dis; 2021; 27(3):728-739. PubMed ID: 33622466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa.
    Mokhele I; Jinga N; Berhanu R; Dlamini T; Long L; Evans D
    BMC Pregnancy Childbirth; 2021 Jun; 21(1):453. PubMed ID: 34182944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.
    Habimana DS; Ngabonziza JCS; Migambi P; Mucyo-Habimana Y; Mutembayire G; Byukusenge F; Habiyambere I; Remera E; Mugwaneza P; Mwikarago IE; Mazarati JB; Turate I; Nsanzimana S; Decroo T; de Jong CB
    Am J Trop Med Hyg; 2021 May; 105(1):47-53. PubMed ID: 33999845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis.
    Tack I; Dumicho A; Ohler L; Shigayeva A; Bulti AB; White K; Mbatha M; Furin J; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3563-e3571. PubMed ID: 33372989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of loss to follow-up among adult tuberculosis patients in Southern Ethiopia: a retrospective follow-up study.
    Watumo D; Mengesha MM; Gobena T; Gebremichael MA; Jerene D
    BMC Public Health; 2022 May; 22(1):976. PubMed ID: 35568853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.
    Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.